 The primary objectives of the Alzheimers Prevention Registry GeneMatch program are to 1 identify and characterize a large cohort of people who are interested in, and may be eligible to participate in, current and future preclinical Alzheimers disease research studies and clinical trials based on their genetic background, and 2 provide information to these individuals about research studies for which they may be eligible, based in part on their genetic background. Cognitively unimpaired individuals age 55 to 75, inclusive, are eligible to enroll in GeneMatch. GeneMatch will provide participants with a genetic sample kit a cheek swab to test for a specific gene called apolipoproteins E APOE. GeneMatch does not disclose the results of the APOE test to participants. GeneMatch may use the APOE test results to match participants to research studies. Participants are under no obligation to pursue these study opportunities. 